⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
globenewswire.com
BIIB
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035
globenewswire.com
BIIB
GILD
BMY
ABBV
MRNA
CRSP
NTLA
EDIT
Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
prnewswire.com
JNJ
ABBV
VRTX
AZN
INCY
BIIB
NVS
ROG
PFE
BMY
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035
globenewswire.com
PFE
AZN
DSNKY
GILD
IMMU
REGN
BIIB
BMY
MRK
NVS
AMGN
LLY
JNJ
ABBV
BNTX
SEGN
RHHBY
Takeda
IQV
PE
United States Home Healthcare Market Analysis Report 2025-2033 Featuring 3M Healthcare, Apple, Arkray, B. Braun Melsungen, BD And Co, F. Hoffmann-La Roche, Fresenius, and Hollister
globenewswire.com
MMM
AAPL
BIIB
BD
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight
globenewswire.com
GSK
TREVI
MRK
AZN
SNY
TEVA
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
Companies Prioritize Revenue Performance with AI, ISG Says
businesswire.com
III
ANAB
XACT
ORCL
CRM
SAP
WDAY
ACN
IBM
MSFT
GOOG
AMZN
ADBE
NOW
INTU
PAYX
FIS
PAYC
SNOW
DDOG
MDB
PLTR
AI
SMCI
NVDA
AMD
INTC
QCOM
META
NFLX
CMCSA
VZ
T
CSCO
HPQ
DELL
PANW
CRWD
FTNT
ZBRA
CDNS
SNPS
MRVL
NXPI
MU
WDC
AMAT
LRCX
KLAC
ASML
ADI
TXN
ON
MPWR
AEHR
ARM
AVGO
AMGN
GILD
BMY
PFE
MRK
JNJ
LLY
ABBV
MDT
ISRG
BIIB
REGN
AZN
NVS
RHHBY
XOM
CVX
SHEL
TCEHY
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
YY
BEKE
NIO
LI
XPEV
RIVN
LCID
TSLA
GM
F
STLA
TM
HMC
VWAGY
BMW
DAI
GE
HON
BA
LMT
RTX
GD
NOC
CAT
DE
AGCO
CNH
J
CHTR
CMCSK
TMUS
ATVI
EA
TTWO
DIS
FOX
PARA
WBD
LYV
AMC
NCLH
CCL
RCL
DAL
UAL
AAL
LUV
JBLU
ALK
MAR
HLT
IHG
WYNN
LVS
MGM
CHKP
Zscaler
AKR
VAR
NICE
BOARD
FORM
PIG
INFSPM
PERF
FULL
CAP
EVER
JED
OPT
XOXO
ELEV
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
globenewswire.com
BIIB
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
prnewswire.com
BIIB
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
businesswire.com
BIIB